Nfl Biosciences SAS

Nfl Biosciences SAS has a fully diluted share count of 12,672,242 shares, with no difference between basic and diluted shares outstanding, indicating no dilution risk from stock options or convertible securities. However, liquidity risk could not be assessed due to the absence of balance-sheet inputs and no going-concern language in source documents.

Profitability and return metrics are not available for Nfl Biosciences SAS, as no valuation snapshot data is provided. Without access to industry_config preferred metrics or cohort medians, a direct comparison to industry peers is not possible at this time.

Segment and geographic exposure data are not disclosed in the available financial reports, making it difficult to assess revenue concentration or geographic diversification.

Analyst estimates suggest a mean price target of 3.13 EUR and a median price target of 2.90 EUR, with a mean recommendation of 2.33 (on a scale from 1=strong buy to 5=strong sell). There are no strong-buy ratings, with two buy and one hold recommendation. No growth trajectory data is available to assess future revenue performance.

Risk factors include the inability to assess liquidity risk due to missing balance-sheet data. Dilution risk is currently low, as there is no difference between basic and diluted shares outstanding. No recent events, such as filings or transcripts, are available to provide additional context on the company's current status.

Operating income −38,8% YoY; Net income −59,5% YoY.

• ▍Operating income −38,8% YoY
• ▍Net income −59,5% YoY

Operating income +34,0% YoY; Net income +44,4% YoY.

• ▍Operating income +34,0% YoY
• ▍Net income +44,4% YoY

Operating income −39,0% YoY; Net income −53,3% YoY.

• ▍Operating income −39,0% YoY
• ▍Net income −53,3% YoY

Operating income −237,5% YoY; Net income −149,8% YoY.

• ▍Operating income −237,5% YoY
• ▍Net income −149,8% YoY